B7-33: relaxin-pathway studies and translational limits
B7-33 is a synthetic peptide modeled on part of relaxin-2 and investigated for signaling through relaxin family peptide receptor 1. Selected animal and cell experiments report vascular and cardiac effects. They are a basis for further research, not proof of a human cardiovascular or antifibrotic treatment.
Identity and formulation
B7-33 is a single-chain experimental analog, whereas serelaxin is recombinant human relaxin-2. Results from one cannot automatically be assigned to the other.
Receptor-selective or functionally selective signaling describes experimental pharmacology. It does not by itself mean the compound avoids every unwanted effect in a whole person.
What the studies show
The studies below concern isolated vessels, short animal exposures and experimentally induced heart injury. Their outcomes are specific to the model and timing. They do not establish reduced hospitalization, improved survival or long-term reversal of fibrosis in patients.
| Study and design | Finding | What it does not establish |
|---|---|---|
| B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin).
Rat vascular experiments and an ex vivo mouse-vessel model Reading scope: PubMed abstract and bibliographic record; not full-text review |
B7-33 enhanced a bradykinin-related relaxation response in rat mesenteric arteries and prevented dysfunction in a conditioned-media mouse-vessel experiment. | There was no overall relaxation effect in the rat renal artery or aorta. The pregnancy-related model was not a clinical preeclampsia trial. |
| B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.
Ischemia-reperfusion injury in male mice, with complementary cardiomyocyte experiments Reading scope: PubMed abstract and bibliographic record; not full-text review |
Treatment was associated with smaller infarct area and better short-term cardiac-function measures than vehicle. | Follow-up and disease induction were experimental; the result does not show benefit in human heart attacks or chronic heart failure. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
How to interpret the findings
A result in one vascular bed should not become a claim that all circulation improves. The negative or unchanged vessel results are part of the evidence.
Preventing damage around a precisely timed experimental injury is different from treating established human disease. Timing, background care and the measured endpoint would need to be addressed in clinical research.
Safety context
The selected experiments do not establish reproductive, pregnancy or long-term human safety. In particular, a vessel model related to preeclampsia is not evidence supporting use during pregnancy.
The absence of a clinical adverse-event table in an animal paper cannot be used as a claim of no human side effects.
Study exposure and units
The papers use both whole-animal exposure and concentrations applied directly to isolated tissues. Those are different quantities and cannot be collapsed into one recommended regimen.
A timing window around experimentally induced ischemia is a feature of the research model, not an instruction for treating cardiovascular symptoms.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Product identity and report checks
Verify the exact B7-33 sequence and formulation. A report for relaxin, serelaxin or another receptor agonist does not establish B7-33 identity.
A biological activity assay can characterize receptor signaling under specified conditions; it cannot demonstrate a clinical heart or fibrosis outcome.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
Common questions
Does B7-33 have human heart-failure evidence in these sources?
No. These sources describe animal and laboratory findings. They should not be presented as patient outcome trials or as evidence that B7-33 substitutes for established care.
Is a relaxin-like effect evidence of general scar reversal?
No. Receptor signaling and short-term cardiac injury measures do not establish reversal of all types of fibrosis or visible scars.
Sources
- B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin). (PubMed abstract and bibliographic record; not full-text review)
- B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice. (PubMed abstract and bibliographic record; not full-text review)